Intratumoral pharmacokinetics: Challenges to nanobiomaterials

Current Pharmaceutical Design

Volumn 21, Issue 22, 2015, Pages 3208-3214

  Al Abd, Ahmed M ^a,b   Al Abbasi, Fahad A ^a   Torchilin, Vladimir P ^a,b  

^a KING ABDULAZIZ UNIVERSITY   (Saudi Arabia)

^b NORTHEASTERN UNIVERSITY   (United States)

Author keywords

Cellular pharmacokinetics; Intratumoral drug distribution; Intratumoral pharmacokinetics; Nanobiomaterials

Indexed keywords

ANTINEOPLASTIC AGENT; NANOBIOMATERIAL; NANOCARRIER; UNCLASSIFIED DRUG; BIOMATERIAL; NANOPARTICLE;

ARTICLE; CELLULAR DISTRIBUTION; DRUG ABSORPTION; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG ELIMINATION; DRUG METABOLISM; DRUG PENETRATION; EFFECTIVE CONCENTRATION; NANOPHARMACEUTICS; PRIORITY JOURNAL; SOLID TUMOR; TISSUE DISTRIBUTION; TUMOR MICROENVIRONMENT; DRUG DELIVERY SYSTEM; HUMAN; METABOLISM; NANOMEDICINE; NEOPLASMS; PATHOLOGY;

ANTINEOPLASTIC AGENTS; BIOCOMPATIBLE MATERIALS; DRUG DELIVERY SYSTEMS; HUMANS; NANOMEDICINE; NANOPARTICLES; NEOPLASMS;

EID: 84938634617     PISSN: 13816128     EISSN: 18734286     Source Type: Journal    
DOI: 10.2174/1381612821666150531170621     Document Type: Article

References (119)

1. Shafer SL. Principles of pharmacokinetics. Wylie Churchill-Davidson's A Practice of Anesthesia 7th ed. Betheseda, Maryland, USA: CRC Press 2003; vol. 2: 29-45.
2. Herfindal ET, Hirschman JL. Clinical pharmacy and therapeutics. USA: Williams & Wilkins 1979.
3. Robinson DC. Topics in Clinical Pharmacology and Therapeutics. USA: Springer 1986; pp. 1-12.
4. Goodman LS. Goodman and Gilman's the pharmacological basis of therapeutics. New York: McGraw-Hill 1996.
5. Derendorf H. Drug Actions: Basic Principles and Theraputic Aspects. USA: CRC press 1995.
6. Rang H, Dale M, Ritter J, Flower R; Elsevier’s Publication, 2006.
7. Herfindal ET, Gourley DR. Textbook of therapeutics: drug and disease management. USA: Williams & Wilkins 1996.
8. Tredan O, Galmarini CM, Patel K, Tannock IF. Drug resistance and the solid tumor microenvironment. J Natl Cancer Inst 2007; 99: 1441-54.
9. Jain RK, Tong RT, Munn LL. Effect of vascular normalization by antiangiogenic therapy on interstitial hypertension, peritumor edema, and lymphatic metastasis: insights from a mathematical model. Cancer Res 2007; 67: 2729-35.
10. Kerbel RS. Antiangiogenic therapy: a universal chemosensitization strategy for cancer? Science 2006; 312: 1171-5.
11. Minchinton AI, Tannock IF. Drug penetration in solid tumours. Nat Rev Cancer 2006; 6: 583-92.
12. Pruijn FB, Sturman JR, Liyanage HS, Hicks KO, Hay MP, Wilson WR. Extravascular transport of drugs in tumor tissue: effect of lipophilicity on diffusion of tirapazamine analogues in multicellular layer cultures. J Med Chem 2005; 48: 1079-87.
13. Hicks KO, Fleming Y, Siim BG, Koch CJ, Wilson WR. Extravascular diffusion of tirapazamine: effect of metabolic consumption assessed using the multicellular layer model. Int J Radiation Oncol* Biol* Phys 1998; 42: 641-9.
14. Al-Abd AM, Al-Abbasi FA, Asaad GF, Abdel-Naim AB. Didox potentiates the cytotoxic profile of doxorubicin and protects from its cardiotoxicity. Eur J Pharmacol 2013; 718: 361-9.
15. Mahmoud AM, Al-Abd AM, Lightfoot DA, El-Shemy HA. Anticancer characteristics of mevinolin against three different solid tumor cell lines was not solely p53-dependent. J Enzyme Inhib Med Chem 2012; 27: 673-9.
16. Al-Abd AM, Hong KY, Song SC, Kuh HJ. Pharmacokinetics of doxorubicin after intratumoral injection using a thermosensitive hydrogel in tumor-bearing mice. J Control Release 2010; 142: 101-7.
17. Banzato A, Bobisse S, Rondina M, et al. A paclitaxel-hyaluronan bioconjugate targeting ovarian cancer affords a potent in vivo therapeutic activity. Clin Cancer Res 2008; 14: 3598-606.
18. Ortiz R, Au JL, Lu Z, Gan Y, Wientjes MG. Biodegradable intraprostatic doxorubicin implants. AAPS J 2007; 9: E241-50.
19. Baker JH, Lindquist KE, Huxham LA, Kyle AH, Sy JT, Minchinton AI. Direct visualization of heterogeneous extravascular distribution of trastuzumab in human epidermal growth factor receptor type 2 overexpressing xenografts. Clin Cancer Res 2008; 14: 2171-9.
20. Weinberg BD, Patel RB, Wu H, et al.Model simulation and experimental validation of intratumoral chemotherapy using multiple polymer implants. Med Biol Eng Comput 2008; 46: 1039-49.
21. Al-Abd AM, Lee JH, Kim SY, Kun N, Kuh HJ. Novel application of multicellular layers culture for in situ evaluation of cytotoxicity and penetration of paclitaxel. Cancer Sci 2008; 99: 423-31.
22. Cowan DS, Tannock IF. Factors that influence the penetration of methotrexate through solid tissue. Int J Cancer 2001; 91: 120-5.
23. Tannock IF, Lee CM, Tunggal JK, Cowan DS, Egorin MJ. Limited penetration of anticancer drugs through tumor tissue: a potential cause of resistance of solid tumors to chemotherapy. Clin Cancer Res 2002; 8: 878-84.
24. Al-Abd AM, Mahmoud AM, El-Sherbiny GA, et al. Resveratrol enhances the cytotoxic profile of docetaxel and doxorubicin in solid tumour cell lines in vitro. Cell Prolif 2011; 44: 591-601.
25. Hoffmann J, Vitale I, Buchmann B, et al. Improved cellular pharmacokinetics and pharmacodynamics underlie the wide anticancer activity of sagopilone. Cancer Res 2008; 68: 5301-8.
26. Lee CM, Tannock IF. Inhibition of endosomal sequestration of basic anticancer drugs: influence on cytotoxicity and tissue penetration. Br J Cancer 2006; 94: 863-9.
27. Pugacheva EN, Ivanov AV, Kravchenko JE, Kopnin BP, Levine AJ, Chumakov PM. Novel gain of function activity of p53 mutants: activation of the dUTPase gene expression leading to resistance to 5-fluorouracil. Oncogene 2002; 21: 4595-600.
28. Banerjee D, Mayer-Kuckuk P, Capiaux G, Budak-Alpdogan T, Gorlick R, Bertino JR. Novel aspects of resistance to drugs targeted to dihydrofolate reductase and thymidylate synthase. Biochim Biophys Acta (BBA)-Mol Basis Dis 2002; 1587: 164-73.
29. Mohan P, Rapoport N. Doxorubicin as a molecular nanotheranostic agent: effect of doxorubicin encapsulation in micelles or nanoemulsions on the ultrasound-mediated intracellular delivery and nuclear trafficking. Mol Pharm 2010; 7: 1959-73.
30. Konerding MA, Miodonski AJ, Lametschwandtner A. Microvascular corrosion casting in the study of tumor vascularity: a review. Scann Microsc 1995; 9: 1233-43; discussion 1243-4.
31. Siemann DW. Tumor vasculature: a target for anticancer therapies. In: Vascular targeted therapies in oncology. Chickester, UK: John Wiley & Sons Ltd. 2006; pp. 1-8.
32. Zambito Y, Di Colo G. Thiolated quaternary ammonium-chitosan conjugates for enhanced precorneal retention, transcorneal permeation and intraocular absorption of dexamethasone. Eur J Pharm Biopharm 2010; 75: 194-9.
33. Grantab R, Sivananthan S, Tannock IF. The penetration of anticancer drugs through tumor tissue as a function of cellular adhesion and packing density of tumor cells. Cancer Res 2006; 66: 1033-9.
34. Wong HL, Shen Z, Lu Z, Wientjes MG, Au JL-S. Paclitaxel tumorpriming enhances siRNA delivery and transfection in 3-dimensional tumor cultures. Mol Pharm 2011; 8: 833-40.
35. Lu D, Wientjes MG, Lu Z, Au JL-S. Tumor priming enhances delivery and efficacy of nanomedicines. J Pharmacol Exp Ther 2007; 322: 80-88.
36. Netti PA, Berk DA, Swartz MA, Grodzinsky AJ, Jain RK. Role of extracellular matrix assembly in interstitial transport in solid tumors. Cancer Res 2000; 60: 2497-503.
37. Choi IK, Strauss R, Richter M, Yun CO, Lieber A. Strategies to increase drug penetration in solid tumors. Front Oncol 2013; 3: 193.
38. Eikenes L, Tari M, Tufto I, Bruland OS, de Lange Davies C. Hyaluronidase induces a transcapillary pressure gradient and improves the distribution and uptake of liposomal doxorubicin (Caelyx) in human osteosarcoma xenografts. Br J Cancer 2005; 93: 81-8.
39. Guedan S, Rojas JJ, Gros A, Mercade E, Cascallo M, Alemany R. Hyaluronidase expression by an oncolytic adenovirus enhances its intratumoral spread and suppresses tumor growth. Mol Ther 2010; 18: 1275-83.
40. Ganesh S, Gonzalez-Edick M, Gibbons D, Van Roey M, Jooss K. Intratumoral coadministration of hyaluronidase enzyme and oncolytic adenoviruses enhances virus potency in metastatic tumor models. Clin Cancer Res 2008; 14: 3933-41.
41. Eikenes L, Bruland OS, Brekken C, Davies Cde L. Collagenase increases the transcapillary pressure gradient and improves the uptake and distribution of monoclonal antibodies in human osteosarcoma xenografts. Cancer Res 2004; 64: 4768-73.
42. Blackburn JS, Rhodes CH, Coon CI, Brinckerhoff CE. RNA interference inhibition of matrix metalloproteinase-1 prevents melanoma metastasis by reducing tumor collagenase activity and angiogenesis. Cancer Res 2007; 67: 10849-58.
43. Kovar JL, Johnson MA, Volcheck WM, Chen J, Simpson MA. Hyaluronidase expression induces prostate tumor metastasis in an orthotopic mouse model. Am J Pathol 2006; 169: 1415-26.
44. Stetler-Stevenson WG. Type IV collagenases in tumor invasion and metastasis. Cancer Metastasis Rev 1990; 9: 289-303.
45. Choi IK, Lee YS, Yoo JY, et al. Effect of decorin on overcoming the extracellular matrix barrier for oncolytic virotherapy. Gene Ther 2010; 17: 190-201.
46. Curran S, Murray GI. Matrix metalloproteinases in tumour invasion and metastasis. J Pathol 1999; 189: 300-8.
47. Zhu L, Perche F, Wang T, Torchilin VP. Matrix metalloproteinase 2-sensitive multifunctional polymeric micelles for tumor-specific co-delivery of siRNA and hydrophobic drugs. Biomaterials 2014; 35: 4213-22.
48. Mok W, Boucher Y, Jain RK. Matrix metalloproteinases-1 and -8 improve the distribution and efficacy of an oncolytic virus. Cancer Res 2007; 67: 10664-8.
49. Gu G, Gao X, Hu Q, et al. The influence of the penetrating peptide iRGD on the effect of paclitaxel-loaded MT1-AF7p-conjugated nanoparticles on glioma cells. Biomaterials 2013; 34: 5138-48.
50. Vaupel P, Hockel M. Blood supply, oxygenation status and metabolic micromilieu of breast cancers: characterization and therapeutic relevance. Int J Oncol 2000; 17: 869-948.
51. Kusumoto T, Maehara Y, Sakaguchi Y, Saku M, Sugimachi K. Hypoxia enhances the lethality of mitomycin C and carboquone against human malignant tumor cells in vitro. Eur Surg Res 1989; 21: 224-31.
52. Luk CK, Veinot-Drebot L, Tjan E, Tannock IF. Effect of transient hypoxia on sensitivity to doxorubicin in human and murine cell lines. J Natl Cancer Inst 1990; 82: 684-92.
53. Siim BG, Menke DR, Dorie MJ, Brown JM. Tirapazamine-induced cytotoxicity and DNA damage in transplanted tumors: relationship to tumor hypoxia. Cancer Res 1997; 57: 2922-8.
54. Lalani AS, Alters SE, Wong A, Albertella MR, Cleland JL, Henner WD. Selective tumor targeting by the hypoxia-activated prodrug AQ4N blocks tumor growth and metastasis in preclinical models of pancreatic cancer. Clin Cancer Res 2007; 13: 2216-25.
55. Cairns R, Papandreou I, Denko N. Overcoming physiologic barriers to cancer treatment by molecularly targeting the tumor microenvironment. Mol Cancer Res 2006; 4: 61-70.
56. Gao ZG, Lee DH, Kim DI, Bae YH. Doxorubicin loaded pHsensitive micelle targeting acidic extracellular pH of human ovarian A2780 tumor in mice. J Drug Target 2005; 13: 391-7.
57. Perche F, Biswas S, Wang T, Zhu L. Torchilin VP, Hypoxiatargeted siRNA delivery. Angew Chem Int Ed Engl 2014; 53: 3362-6.
58. Kang GD, Cheon SH, Song SC. Controlled release of doxorubicin from thermosensitive poly(organophosphazene) hydrogels. Int J Pharm 2006; 319: 29-36.
59. Zhao Y, Ji T, Wang H, Li S, Zhao Y, Nie G. Self-assembled peptide nanoparticles as tumor microenvironment activatable probes for tumor targeting and imaging. J Control Release 2014; 177: 11-9.
60. Kang GD, Cheon SH, Khang G, Song SC. Thermosensitive poly(organophosphazene) hydrogels for a controlled drug delivery. Eur J Pharm Biopharm 2006; 63: 340-6.
61. Lee ES, Gao Z, Kim D, Park K, Kwon IC, Bae YH. Super pHsensitive multifunctional polymeric micelle for tumor pH(e) specific TAT exposure and multidrug resistance. J Control Release 2008; 129: 228-36.
62. Zeng Y, Zhang S, Jia M, et al. Hypoxia-sensitive bis(2-(2'-benzothienyl)pyridinato-N, C(3'))iridiumpoly n-butyl cyanoacrylate/chitosan nanoparticles and their phosphorescence tumor imaging in vitro and in vivo. Nanoscale 2013; 5: 12633-44
63. Shi J, Votruba AR, Farokhzad OC, Langer R. Nanotechnology in drug delivery and tissue engineering: from discovery to applications. Nano Lett 2010; 10: 3223-30.
64. Elstad NL, Fowers KD. OncoGel (ReGel/paclitaxel)--clinical applications for a novel paclitaxel delivery system. Adv Drug Deliv Rev 2009; 61: 785-94.
65. Zentner GM, Rathi R, Shih C, et al. Biodegradable block copolymers for delivery of proteins and water-insoluble drugs. J Control Release 2001; 72: 203-15.
66. Lukianova-Hleb EY, Ren X, Sawant RR, Wu X, Torchilin VP, Lapotko DO. On-demand intracellular amplification of chemoradiation with cancer-specific plasmonic nanobubbles. Nat Med 2014; 20: 778-84.
67. El-Sayed MA, Shabaka AA, El-Shabrawy OA, et al. Tissue distribution and efficacy of gold nanorods coupled with laser induced photoplasmonic therapy in ehrlich carcinoma solid tumor model. PLoS One 2013; 8: e76207.
68. Al-Abd AM, Lee SH, Kim SH, et al. Penetration and efficacy of VEGF siRNA using polyelectrolyte complex micelles in a human solid tumor model in-vitro. J Control Release 2009; 137: 130-5.
69. Ridge JA, Collin C, Bading JR, et al. Increased adriamycin levels in hepatic implants of rabbit Vx-2 carcinoma from regional infusion. Cancer Res 1988; 48: 4584-7.
70. Weinberg BD, Ai H, Blanco E, Anderson JM, Gao J. Antitumor efficacy and local distribution of doxorubicin via intratumoral delivery from polymer millirods. J Biomed Mater Res A 2007; 81: 161-70.
71. Evangelio JA, Abal M, Barasoain I, et al. Fluorescent taxoids as probes of the microtubule cytoskeleton. Cell Motil Cytoskeleton 1998; 39: 73-90.
72. Souto AA, Acuña AU, Andreu JM, Barasoain I, Abal M, Amat-Guerri F. New fluorescent water-soluble taxol derivatives. Angew Chem Int Ed Eng 1996; 34: 2710-2.
73. Schwarz SW, Welch MJ. Applications of enzyme biotechnology. Springer 1991; pp. 1-13.
74. Al-Abd AM, Lee SH, Kuh HJ. Simultaneous evaluation of cellular vitality and drug penetration in multicellular layers of human cancer cells. J Korean Pharm Sci 2006; 36: 293-8.
75. Evans CJ, Phillips RM, Jones PF, et al. A mathematical model of doxorubicin penetration through multicellular layers. J Theor Biol 2009; 257: 598-608.
76. Wilson WR, Hicks KO. Measurement of extravascular drug diffusion in multicellular layers. Br J Cancer 1999; 79: 1623-6.
77. Leu AJ, Berk DA, Lymboussaki A, Alitalo K, Jain RK. Absence of functional lymphatics within a murine sarcoma: a molecular and functional evaluation. Cancer Res 2000; 60: 4324-7.
78. Mocanu JD, Yip KW, Skliarenko J, et al. Imaging and modulating antisense microdistribution in solid human xenograft tumor models. Clin Cancer Res 2007; 13: 5935-41.
79. Michael M, Doherty MM. Tumoral drug metabolism: overview and its implications for cancer therapy. J Clin Oncol 2005; 23: 205-29.
80. Sengupta S, Eavarone D, Capila I, et al. Temporal targeting of tumour cells and neovasculature with a nanoscale delivery system. Nature 2005; 436: 568-72.
81. Kim JB, Three-dimensional tissue culture models in cancer biology. Semin Cancer Biol 2005; 15: 365-77.
82. Kuh HJ, Jang SH, Wientjes MG, Weaver JR, Au JL. Determinants of paclitaxel penetration and accumulation in human solid tumor. J Pharmacol Exp Ther 1999; 290: 871-80.
83. Chen H-S, Gross J. Physiologically based pharmacokinetic models for anticancer drugs. Cancer Chemotherapy Pharmacol 1979; 2: 85-94.
84. Gabizon A, Papahadjopoulos D. Liposome formulations with prolonged circulation time in blood and enhanced uptake by tumors. Proc Natl Acad Sci 1988; 85: 6949-53.
85. Min KH, Park K, Kim YS, et al. Hydrophobically modified glycol chitosan nanoparticles-encapsulated camptothecin enhance the drug stability and tumor targeting in cancer therapy. J Control Release 2008; 127: 208-18.
86. Huang P, Song H, Wang W, et al. Integrin-targeted zwitterionic polymeric nanoparticles with acid-induced disassembly property for enhanced drug accumulation and release in tumor. Biomacromolecules 2014; 15: 3128-38.
87. Yingyuad P, Mevel M, Prata C, Kontogiorgis C, Thanou M, Miller AD. Enzyme-triggered PEGylated siRNA-nanoparticles for controlled release of siRNA. J RNAi Gene Silencing 2014; 10: 490-9.
88. Abouzeid AH, Patel NR, Rachman IM, Senn S, Torchilin VP. Anticancer activity of anti-GLUT1 antibody-targeted polymeric micelles co-loaded with curcumin and doxorubicin. J Drug Target 2013; 21: 994-1000.
89. Kufe DW, Pollock RE, Weichselbaum RR, et al. Principles of Pharmacokinetics. New York, USA: BC Decker Inc. 2003.
90. Van De Waterbeemd H, Smith DA, Beaumont K, Walker DK. Property-based design: optimization of drug absorption and pharmacokinetics. J Med Chem 2001; 44: 1313-33.
91. Torchilin VP. Passive and active drug targeting: drug delivery to tumors as an example. Handb Exp Pharmacol 2010: 3-53.
92. Abdallah HM, Al-Abd AM, El-Dine RS, El-Halawany AM. Pglycoprotein inhibitors of natural origin as potential tumor chemosensitizers: a review. J Adv Res 2014.
93. Ling V, Thompson LH. Reduced permeability in CHO cells as a mechanism of resistance to colchicine. J Cell Physiol 1974; 83: 103-16.
94. Zeng H, Bain LJ, Belinsky MG, Kruh GD. Expression of multidrug resistance protein-3 (multispecific organic anion transporter-D) in human embryonic kidney 293 cells confers resistance to anticancer agents. Cancer Res 1999; 59: 5964-7.
95. Maliepaard M, van Gastelen MA, de Jong LA, et al. Overexpression of the BCRP/MXR/ABCP gene in a topotecan-selected ovarian tumor cell line. Cancer Res 1999; 59: 4559-63.
96. Fawell S, Seery J, Daikh Y, et al. Tat-mediated delivery of heterologous proteins into cells. Proc Natl Acad Sci USA 1994; 91: 664-8.
97. Torchilin VP, Rammohan R, Weissig V, Levchenko TS. TAT peptide on the surface of liposomes affords their efficient intracellular delivery even at low temperature and in the presence of metabolic inhibitors. Proc Natl Acad Sci USA 2001; 98: 8786-91.
98. Morris MC, Vidal P, Chaloin L, Heitz F, Divita G. A new peptide vector for efficient delivery of oligonucleotides into mammalian cells. Nucleic Acids Res 1997; 25: 2730-6.
99. Hodoniczky J, Sims CG, Best WM, Bentel JM, Wilce JA. The intracellular and nuclear-targeted delivery of an antiandrogen drug by carrier peptides. Biopolymers 2008; 90: 595-603.
100. Vazquez O, Blanco-Canosa JB, Vazquez ME, Martinez-Costas J, Castedo L, Mascarenas JL. Efficient DNA binding and nuclear uptake by distamycin derivatives conjugated to octa-arginine sequences. ChemBioChem 2008; 9: 2822-9.
101. Goren D, Horowitz AT, Tzemach D, Tarshish M, Zalipsky S, Gabizon A. Nuclear delivery of doxorubicin via folate-targeted liposomes with bypass of multidrug-resistance efflux pump. Clin Cancer Res 2000; 6: 1949-57.
102. Khalil IA, Kogure K, Futaki S, Harashima H. High density of octaarginine stimulates macropinocytosis leading to efficient intracellular trafficking for gene expression. J Biol Chem 2006; 281: 3544-51.
103. Biswas S, Torchilin VP, Nanopreparations for organelle-specific delivery in cancer. Adv Drug Deliv Rev 2014; 66: 26-41.
104. Weissig V, Boddapati S, D'souza G, Cheng S. Targeting of lowmolecular weight drugs to mammalian mitochondria. Drug Des Rev Online 2004; 1: 15-28.
105. Ross MF, Kelso GF, Blaikie FH, et al. Lipophilic triphenylphosphonium cations as tools in mitochondrial bioenergetics and free radical biology. Biochemistry (Mosc) 2005; 70: 222-30.
106. Yasuzaki Y, Yamada Y, Harashima H. Mitochondrial matrix delivery using MITO-Porter, a liposome-based carrier that specifies fusion with mitochondrial membranes. Biochem Biophys Res Commun 2010; 397: 181-6.
107. Weissig V, Lizano C, Torchilin VP. Selective DNA release from DQAsome/DNA complexes at mitochondria-like membranes. Drug Deliv 2000; 7: 1-5.
108. Lanford RE, Kanda P, Kennedy RC. Induction of nuclear transport with a synthetic peptide homologous to the SV40 T antigen transport signal. Cell 1986; 46: 575-82.
109. Akita H, Kudo A, Minoura A, et al. Multi-layered nanoparticles for penetrating the endosome and nuclear membrane via a step-wise membrane fusion process. Biomaterials 2009; 30: 2940-9.
110. Thekkedath R, Koshkaryev A, Torchilin VP. Lysosome-targeted octadecyl-rhodamine B-liposomes enhance lysosomal accumulation of glucocerebrosidase in Gaucher's cells in vitro. Nanomedicine (Lond) 2013; 8: 1055-65.
111. Nylandsted J, Rohde M, Brand K, Bastholm L, Elling F, Jaattela M. Selective depletion of heat shock protein 70 (Hsp70) activates a tumor-specific death program that is independent of caspases and bypasses Bcl-2. Proc Natl Acad Sci USA 2000; 97: 7871-6.
112. Sahay G, Gautam V, Luxenhofer R, Kabanov AV. The utilization of pathogen-like cellular trafficking by single chain block copolymer. Biomaterials 2010; 31: 1757-64.
113. Liu Z, Davis C, Cai W, He L, Chen X, Dai H. Circulation and longterm fate of functionalized, biocompatible single-walled carbon nanotubes in mice probed by Raman spectroscopy. Proc Natl Acad Sci USA 2008; 105: 1410-5.
114. Zavaleta C, De La Zerda A, Liu Z, et al. Noninvasive Raman spectroscopy in living mice for evaluation of tumor targeting with carbon nanotubes. Nano Lett 2008; 8: 2800-5.
115. Ocak I, Bernardo M, Metzger G, et al. Dynamic contrast-enhanced MRI of prostate cancer at 3 T: a study of pharmacokinetic parameters. Am J Roentgenol 2007; 189: W192-201.
116. Chen MH, Chang CH, Chang YJ, et al. MicroSPECT/CT imaging and pharmacokinetics of 188Re-(DXR)-liposome in human colorectal adenocarcinoma-bearing mice. Anticancer Res 2010; 30: 65-72.
117. Hoang B, Lee H, Reilly RM, Allen C. Noninvasive monitoring of the fate of 111In-labeled block copolymer micelles by high resolution and high sensitivity microSPECT/CT imaging. Mol Pharm 2009; 6: 581-92.
118. Patel V, Papineni RV, Gupta S, Stoyanova R, Ahmed MM. A realistic utilization of nanotechnology in molecular imaging and targeted radiotherapy of solid tumors. Radiat Res 2012; 177: 483-95.
119. Chaplin D, Hill S. Temporal heterogeneity in microregional erythrocyte flux in experimental solid tumours. Br J Cancer 1995; 71: 1210.